|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Service de Physiologie-Explorations
Fonctionnelles and the Centre de la Drépanocytose, Hôpital
Henri Mondor, APHP et Université Paris XII, France; and
Unité de Biorhéologie, Université Paris VI et LBHP
CNRS ESA 7057, France.
Interactions between the endothelium and erythrocytes may
contribute to the vascular complications of sickle cell disease (SCD).
Endothelium-derived nitric oxide (NO) plays a major role in the
regulation of vasomotor tone in response to wall shear stress (WSS)
variations and pharmacologic stimuli. However, little is known about
endothelial NO production in patients with steady-state SCD. We
investigated endothelial NO production in response to flow or
vasoactive agonists in 16 homozygous patients with steady-state SCD and
15 controls. Flow-mediated dilation (FMD), arterial diameter changes in
response to 100% oxygen inhalation, blood viscosity, and calculated
WSS were determined in all patients and controls. At baseline, WSS was
higher in SCD patients than in controls, whereas arterial diameter was
similar. In patients with SCD, FMD was impaired (1.73% ± 0.44% vs
3.97% ± 0.24% in the controls, P < .001) and
vasoconstriction in response to 100% oxygen was abolished. Using
venous occlusion plethysmography, forearm blood flow (FBF) was
evaluated in response to acetylcholine, nitro-monomethyl-L-arginine (L-NMMA), and sodium nitroprusside (SNP) in subgroups of 9 controls and
7 patients with SCD. Acetylcholine induced a significantly greater FBF
increase in the patients (9.7 ± 2.9 mL/min/100 mL of forearm volume
vs 2.5 ± 1.5 mL/min/100 mL in the controls, P < .001), whereas responses to L-NMMA and SNP were
similar. These results suggest that endothelial dysfunction may prevent
the arterial diameter of patients with SCD from adapting to chronic or
acute shear stress elevations. This may contribute to the
pathophysiology of vaso-occlusive crisis in patients with SCD.
(Blood. 2001;97:1584-1589) Vaso-occlusive crisis is a characteristic
manifestation of sickle cell disease (SCD). One current hypothesis
suggests that interactions between sickle red blood cells (SSRBCs) and
the endothelium may contribute to the pathogenesis of vaso-occlusive
crisis.1 Sickle erythrocytes may occlude microvessels
directly by adhering to the endothelium or indirectly by altering
endothelial functions such as endothelium-dependent vasodilation. Thus,
enhanced interactions between SSRBCs and the vascular endothelium on
one hand and abnormal vasomotor tone regulation on the other may
contribute synergistically to the occurrence of vaso-occlusive crisis.
In vivo studies have identified specific hemodynamic conditions in the
microcirculation of patients with SCD. During the intervals between
crises, there is an increase in peripheral blood flow2 with
a periodic microcirculatory flow pattern, which may compensate for the
alterations in red blood cell rheology.3 Arteriolar
diameter is increased during vaso-occlusive crisis as compared with
steady-state phases of the disease.4 Thus, the
relationship between endothelial regulation of vascular tone and red
blood cell rheology seems to play a key role in SCD.5
However, to our knowledge, no studies have investigated the
vasoreactive properties of large muscular arteries.
Among endothelial mediators, nitric oxide (NO) plays a central role by
contributing to the control of normal vascular tone, cellular adhesion,
platelet aggregation, and thrombosis.6 Evidence that
SSRBCs may induce endothelial dysfunction has been obtained in
vitro7,8 and in animal models.9,10 SSRBCs
impair endothelium-dependent relaxation in vitro when applied on
vascular strips7 and impair endothelial production of
prostanoids.9 The NO pathway may also play a critical role
in maintaining cerebral blood flow in experimental animals given
intravenous infusions of SSRBCs.11 However, little is
known about human endothelial dysfunction in patients with SCD.
Evidence supporting a decrease in NO production or release during
vaso-occlusive crises has been reported recently: A decrease in NO
metabolites was associated with a rise in plasma vascular cell adhesion
molecule (VCAM)-1 levels, suggesting an inverse relationship between NO
and adhesion molecules in patients with SCD.1
In the present study, we evaluated NO-mediated vasodilation in patients
with steady-state SCD. Endothelial NO synthase (NOS) is constitutively
expressed by endothelial cells and is stimulated further by
receptor-dependent agonists such as acetylcholine or bradykinin.12 Wall shear stress (WSS), which reflects
mechanical forces exerted on endothelial cells, is another important
physiologic stimulus of endothelial NOS activity and is thought to be
responsible for basal NOS activity and for the continuous in vivo
release of NO from the endothelium.13 The putative
mechanism underlying flow-mediated vasodilation (FMD) is NO release by
the endothelium following stimulation by an increase in
WSS.14,15 Vascular remodeling has been observed following
chronic elevation or diminution of WSS, which induces an increase or a
decrease in arterial diameter, respectively.16,17 The
long-term regulation of arterial diameter is structural and may
counter-regulate variations in WSS. In SCD, the increased cardiac
output18 and relative increase in blood viscosity19 contribute to increase WSS.
We designed the study to evaluate in vivo endothelial function and
NO-mediated vasodilation in response to both WSS and pharmacologic modulation of NOS activity in patients with steady-state SCD. Using a
high-resolution, A-mode, ultrasound and echo-tracking device to monitor
brachial artery diameter, we determined WSS at baseline and
investigated the vasodilator response to increased forearm blood flow
(FBF) generated by reactive hyperemia. Studies were also performed
during 100% oxygen inhalation to assess the vasoconstrictor response
to decreased FBF. In addition, changes in FBF were explored using
venous occlusion plethysmography (VOP) to assess vasodilator responses
to acetylcholine and sodium nitroprusside (SNP) as well as the
vasoconstrictor response to the selective inhibitor of NO synthesis
nitro-monomethyl-L-arginine (L-NMMA).
Study population
All study subjects underwent brachial artery ultrasound scanning to
determine the arterial diameter and local blood flow at baseline and
under hyperoxia as well as FMD. In subgroups of 9 controls and 7 patients, FBF measurements were obtained using VOP.
The various techniques used in this study to evaluate endothelial
function were performed in a random order on different days within the
same week. Patients who developed clinical events between evaluations
were to be excluded. All subjects gave their written informed consent,
and the study protocol was approved by our institutional review board.
Evaluation of flow-mediated dilation
Hyperoxia Subjects inhaled 100% oxygen for 10 minutes via an occlusive mask. Brachial artery flow was calculated at baseline and after 5 and 10 minutes of 100% oxygen inhalation, using the formula Q = V r2, where V is the mean blood velocity measured
over 3 cardiac cycles by pulsed-wave Doppler coupled with
high-resolution B-mode ultrasound (Acuson 128 XP 10, Mountain View, CA)
and r is the radius of the artery at the flow measurement site.
FBF measurement by VOP In a first subgroup of patients, FBF was measured at the forearm using strain-gauge VOP as previously described.21 Briefly, a mercury-in-silastic strain gauge was placed around the widest portion of the upper third of the forearm. The strain gauge was electrically coupled to a plethysmograph (Perivein JSI 0539/l, ETNA, Noisy le Gd, France) calibrated to measure normalized changes in volume. The plethysmographic FBF tracings were connected to a Gould chart recorder for analysis (Gould Electrics, Ballainvilliers, France). For each measurement, venous flow was occluded just proximal to the elbow by rapidly inflating a blood pressure cuff to 40 mmHg. A wrist cuff was inflated to suprasystolic pressures starting 1 minute before each measurement to exclude the hand circulation from blood flow determination. FBF measurements are reported in milliliters per minute per 100 milliliters of forearm volume, and each value is the mean of at least 3 determinations. Systolic blood pressure, diastolic blood pressure, mean blood pressure, and heart rate were monitored continuously (Finapres 2300, Ohmeda). All studies were performed in the morning in a quiet room kept at a controlled temperature of 22°C. While the subject was in the supine position, a catheter (Seldicath, diameter 1.0, Teflon ORX, 3P, Plastimed, St Leu la Forêt, France) was inserted after local anesthesia (1% xylocaine) into the brachial artery of the nondominant arm, which was elevated to a level slightly above the right atrium. After insertion of the catheter, a 30-minute rest was observed to ensure hemodynamic stability. To establish resting control FBF values, 0.9% saline was administered for 30 minutes, and blood flow measurements were repeated until a stable baseline condition was obtained. Infusion of vasoactive agents was then started. Between each series of drug injections, FBF was allowed to return to its basal value (this required approximately 20 minutes); during these intervals, 0.9% saline was infused. Three drugs were used to explore endothelial function, as previously described22: (1) acetylcholine (Pharmacie Centrale des Hôpitaux, Paris, France), an M3 muscarinic agonist that stimulates endothelial NO production, as a continuous infusion at rates of 4, 8, and 16 µg/min; (2) SNP (Nitriate, Laboratoires SERB, Paris, France), an NO donor used to study endothelium-independent vasodilation, at rates of 0.5, 0.8, and 1 µg/min; and (3) L-NMMA (Clinalpha, Laufelfingen, Switzerland) at rates of 4, 8, and 16 µM/min. Each concentration of each drug was injected into the brachial artery for 5 minutes. Drugs were administered in random order.Blood viscosity Blood viscosity ( ) was measured in all patients as
previously described.23 Briefly, blood was withdrawn and
processed immediately. Blood viscosity was measured using a calibrated
coaxial cylinder Couette viscometer (Chaix-Meca, Nancy, France) at
shear rates of 0.01 s 1 to 33 s1 and under
atmospheric pressure. Measurements were done according to a
well-established protocol, at the native hematocrit, and at a
temperature of 37°C. The shear-thinning curve, which is the viscosity
decrease plotted against the shear rate, was then analyzed using
Quemada's model,24 and viscosity at 100 s1
was derived.
Wall shear stress WSS was calculated according to Hoeks et al25 from blood viscosity and local blood flow in the brachial artery. Assuming laminar flow, WSS was calculated using the Poiseuille formula: WSS = 4Q/(r3), where WSS is the wall shear
stress, the blood viscosity, Q the local blood flow at rest, and r
the arterial radius at the blood flow measurement
site.26
Statistical analysis All data are reported as the means ± SEMs. Analysis of variance (ANOVA) for repeated measurements was used to assess the group effect, order, dose effect, and interaction for the absolute values and percent changes. Paired t tests were then used for pairwise comparisons. Group comparisons were by unpaired t tests. P values of less than .05 were considered statistically significant.
Study population The patients with SCD and the control subjects were similar regarding age, height, weight, blood pressure, and heart rate at rest (Table 1). Blood hemoglobin and hematocrit levels were significantly lower in the patients than in the controls (hemoglobin: 86 ± 3 vs 140 ± 3 g/L [8.6 ± 0.3 vs 14 ± 0.3 g/dL], respectively, P < .001; and hematocrit: 0.27 ± 0.01 vs 0.42 ± 0.01, [27% ± 1.1% vs 41.9% ± 1%], respectively, P < .001). Blood viscosity was significantly lower in the patients than in the controls (3.6 ± 0.1 vs 4.03 ± 0.15 mPa.s, respectively, P < .05). However, the ratio of viscosity over hematocrit was significantly higher in the patients (13.6 ± 0.6 vs 9.6 ± 0.3 in the controls, P < .001), indicating marked alteration of the physical properties of red blood cells in SCD. No short-term adverse effects were observed in any of our patients after the investigations. In the 3 months following the study, a single patient had a minor vaso-occlusive crisis. This patient did not exhibit any features of note during the study.Evaluation of endothelial function using brachial arterial diameter monitoring To evaluate WSS-mediated vasodilation, we measured the percentage increase in arterial diameter following a hyperemia test, as described in "Patients, materials, and methods." We also monitored changes in brachial artery flow to compare blood flow variations and arterial diameter variations. As shown in Table 2, the brachial artery flow and baseline brachial artery diameter tended to be higher in the patients than in the controls, although the difference was not statistically significant. However, the calculated WSS at baseline was significantly higher in the patients than in the controls.
In response to hyperemia, brachial artery flow increased to a greater
value in the patients than the controls, but the percentage flow
increase was similar in the 2 groups (+193% vs +234% in the patients
and controls, respectively, P > .05). However, as shown in Figure 1, FMD was 56% lower in the
patients than in the controls (1.73% ± 0.44% vs
3.97% ± 0.24%, P < .001 by t test). This
marked FMD decrease in the patients was observed despite the fact that the calculated WSS reached a higher value in the patients following hyperemia, indicating blunted reactivity of the endothelium to an
increase in flow.
We then sought to determine whether a decrease in WSS was associated
with reduced vasoconstriction in the patients. Hyperoxia is known to
reduce cardiac output, mainly via an increase in peripheral resistance.
Upon exposure to 100% oxygen, brachial artery blood flow decreased to
a similar extent in the 2 groups (
Pharmacologic evaluation of FBF using VOP We evaluated endothelial responses to pharmacologic stimulation and inhibition in the patients and controls to explore another major pathway of NOS activation. Acetylcholine is a potent M3 receptor agonist responsible for calcium-dependent enhancement of NO production by endothelial cells.As shown in Figure 3, FBF was
significantly higher at baseline in the patients than in the controls
(2.5 ± 0.3 vs 1.6 ± 0.2 mL/min/100 mL, respectively,
P < .05). This difference was stable throughout the VOP
procedure. Figure 3 shows that the FBF increase after a 16 µg/min
acetylcholine infusion was significantly greater in the patients than
in the controls (9.7 ± 2.9 vs 2.5 ± 1.5 mL/min/100 mL,
respectively, P < .001 by the Scheffé test). This
increase was dose-dependent, and ANOVA of the effects of 4, 8, and 16 µg/min acetylcholine showed significantly larger FBF increases in the patients than in the controls (P < .001). When FBF values
recorded during acetylcholine infusions were normalized for baseline
FBF values (to correct for the flow difference at baseline), similar results were obtained (data not shown).
Endothelial NO production is continuously stimulated by
shear stress, and NO exerts a continuous and regulated
vasodilator effect. We used infusion of the specific NOS inhibitor
L-NMMA to evaluate the biologic effect of basal NO on vascular tone. Figure 4 shows that L-NMMA induced
significant vasoconstriction in both groups, but ANOVA of FBF
variations showed a nonsignificant difference between the 2 groups when
FBF values were expressed as raw data. However, the percentage
vasoconstriction from baseline in response to 16 µM/min L-NMMA was
significantly lower in the patients than in the controls
(
Endogenously produced NO diffuses out of the endothelial cells and
promotes relaxation of smooth muscle cells through the production of
cyclic guanosine monophosphate by soluble guanylate cyclase. To
evaluate endothelium-independent vasodilation, we induced direct smooth
muscle cell relaxation by administering the potent nitrovasodilator
SNP. As shown in Figure 5, we found a
similar dose-dependent SNP-induced vasodilation in both groups (nonsignificant by ANOVA).
We found evidence of marked alteration in WSS-induced endothelium-dependent vasodilation in patients with SCD. Both the high baseline WSS and the impaired FMD in the patients suggest failure of muscular arteries to adjust their internal diameter in response to mechanical stimulation. The blunted oxygen-induced vasoconstriction also points to a decreased endothelial response to flow variations. The increased acetylcholine-induced vasodilation and unchanged SNP-induced vasodilation argue for a selective alteration in shear stress signal transduction in the vascular wall rather than for a reduction in NOS activity. This is further supported by the similar baseline NO release in the patients and controls as assessed by the response to L-NMMA. Numerous studies have found evidence that endothelial function plays a critical role in protecting against platelet activation, thrombosis, and vascular remodeling. Endothelial cells respond to circulating vasoactive compounds and to variations in WSS, the dragging frictional force created by blood flow and blood viscosity.13 WSS stimulates the release of vasoactive substances such as NO, modifies gene expression, and alters cell metabolism and morphology.27 One consequence of an acute or chronic increase in WSS in large and small arteries is an adjustment in vessel caliber to restore WSS to its baseline value.16 Both acute and chronic vessel diameter increases in response to shear stress have been shown to involve endothelial release of NO. A sustained decrease in WSS leads to a diminution in arterial caliber, and the capacity for vasodilation and vasoconstriction adjusts to the level corresponding to the new size of the vessel.17,28 Similarly, Tronc et al have shown that a sustained WSS increase induces an NO-dependent increase in arterial diameter that normalizes WSS regardless of blood flow.16 Therefore, failure of vessels to adjust their diameter to WSS changes probably reflects an impairment in the basal or stimulated release of NO. In the present study, we first investigated baseline brachial artery flow, blood viscosity, and brachial artery diameter in patients with SCD to determine baseline WSS. In accordance with previous studies showing a 50% increase in cardiac output in SCD patients,18 we found that brachial artery flow was about 50% higher in the SCD patients than in the controls. Blood viscosity was slightly lower in the patients, but this difference was due mainly to a lower hematocrit level. When blood viscosity was normalized for the hematocrit using Chien's curves of blood viscosities by cell concentrations,29 viscosity was considerably higher in the patients than in the controls. This observation is consistent with previous data from patients with SCD of similar severity; it reflects the lack of deformability of sickle cells, even during exposure to high oxygen levels.19 Because the SCD patients had a marked FBF increase and a small blood viscosity decrease, their baseline brachial artery WSS was higher than in the controls. Interestingly, baseline brachial artery diameter was similar in the patients and controls, indicating impaired arterial diameter adjustment to the chronically increased WSS in the patients. Moreover, an acute increase in WSS in response to reactive hyperemia induced a smaller increase in brachial artery diameter in the patients than in the controls. This difference occurred although the relative increase in brachial artery flow generated by hyperemia was similar in the 2 groups. The slight increase in arterial diameter in the patients as compared with the controls could suggest a decrease in vasodilation reserve, the artery being closer to maximum dilation. However, the difference between baseline diameters was not statistically significant. Moreover, previous studies have shown that a chronic increase in arterial diameter in response to WSS indicates vascular remodeling rather than vasodilation, and remodeled vessels would be expected to have a normal vasodilation reserve.17,28 Overall, these results strongly suggest that systemic arteries in patients with SCD fail to adjust appropriately to chronic or acute increases in WSS. A decrease in WSS can be obtained by decreasing the brachial artery flow. This was achieved in our study by inhalation of pure oxygen. An increase in arterial oxygen content is known to induce marked vasoconstriction of the microcirculation, leading to an increase in peripheral resistance. Hyperoxia and increased resistance are responsible for a decrease in cardiac output.30 Following inhalation of 100% oxygen for 10 minutes, we observed similar decreases in brachial artery flow in the patients and controls. However, the decrease in brachial artery diameter was considerably smaller in the patients. This finding is consistent with a previous report of a very small hyperoxia-induced decrease in arteriolar diameter in sickle transgenic mice.31 The authors suggested that the altered microvascular response to oxygen resulted from blood rheologic changes or intrinsic differences in endothelial cell/vascular smooth muscle function. In the light of the present results in humans, the impaired vasoconstrictor response to hyperoxia was probably due, at least in part, to endothelial dysfunction. However, we cannot exclude that other effects of oxygen were involved in the absence of a vasoconstrictive response in our patients with SCD. As stated above, in vitro and in vivo studies in large and small arteries have indicated that acute or chronic flow-induced dilation is mediated by NO released by the endothelium. Failure of muscular arteries to adjust their diameter in response to changes in WSS could theoretically result from several mechanisms, including impaired synthesis or release of NO, acceleration of NO degradation, or alterations in the endothelial-sensitive signal-transduction pathway leading to endothelial NOS activation. To assess this issue, we used plethysmography to measure FBF during infusion of the endothelium-dependent vasodilator acetylcholine and the NO-donor SNP in the patients and controls. Interestingly, we found that the vasodilator response to acetylcholine was considerably stronger in the SCD patients than in the controls, suggesting enhanced synthesis and/or release of NO induced by pharmacologic stimuli. The vasodilator response to SNP was similar in the patients and controls, indicating that the smooth muscle vasodilator response to NO was normal in patients with SCD. The potentiated endothelium-dependent response to acetylcholine, together with the normal nitrovasodilator (SNP) response, suggests increased production and/or decreased degradation of NO in SCD patients. These findings are consistent with previous animal studies suggesting that endothelial NOS expression and/or activity may be increased in SCD10,32,33 and with other studies showing that endothelial NOS expression is increased by shear stress.34,35 Increased endothelium-dependent vasodilation to acetylcholine has also been demonstrated in patients with severe anemia due to various causes. In these patients, the vasoconstrictor response to the selective NO formation inhibitor L-NMMA was potentiated, and correction of anemia was associated with a return of the increased acetylcholine response to the control level. Because the vasoconstrictor response to L-NMMA is thought to be a reliable indicator of basal NO release, this finding was taken as evidence that low hematocrit levels potentiate NO-mediated vasodilation, possibly by increasing the half-life of NO. In our study in SCD patients, the absolute vasoconstrictor response to L-NMMA was similar in the patients and controls, and the percentage response was smaller in the patients. This may indicate that the amount of NO released by the endothelium under basal conditions in SCD patients is similar or lower than in normal subjects. An increase in the basal production of NO would be expected in SCD patients because of their high basal WSS values. Again, this may indicate an inappropriately low level of NO release under basal conditions in patients with steady-state SCD. These observations suggest that endothelial NO is functionally active in patients with SCD. Possible explanations for the increased vasodilator response to acetylcholine include an increase in the half-life of NO and up-regulation of endothelial NOS activity and/or expression. The main finding from our study is that endothelium-dependent vasodilation mediated by WSS was markedly impaired in patients with SCD. Because WSS is the main physiologic stimulus of NOS, and because variations in WSS lead to adjustments in vessel diameter, this impairment may play a pivotal role in the pathogenesis of vaso-occlusive crisis in patients with SCD. Failure of vessel diameter to adjust to rheologic conditions may favor interactions between SSRBCs and the vessel wall, thereby precipitating vaso-occlusive events. Moreover, insufficient release of NO, which not only induces smooth muscle cell relaxation but also inhibits platelet adhesion and aggregation, decreases the expression of adhesion molecules such as VCAM-1 and may therefore have important pathogenic consequences in SCD. In conclusion, SCD is characterized by an impairment of the endothelial response to chronic or acute WSS variations in the brachial artery. One likely mechanism of this abnormality is decreased mechanical transduction in endothelial cells secondary to chronic elevation of WSS. Further studies are needed to clarify the complex mechanisms underlying the impaired response to WSS variations.
Submitted May 1, 2000; accepted November 8, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Laurent Belhassen, Hôpital Henri
Mondor, Service de Physiologie
1.
Stuart MJ, Setty BN.
Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.
Blood.
1999;94:1555-1560 2. Lonsdorfer J, Bogui P, Otayeck A, Bursaux E, Poyart C, Cabannes R. Cardiorespiratory adjustments in chronic sickle cell anemia. Bull Eur Physiopathol Respir. 1983;19:339-344[Medline] [Order article via Infotrieve]. 3. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med. 1984;311:1534-1538[Abstract]. 4. Lipowsky HH, Sheikh NU, Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest. 1987;80:117-127. 5. Rodgers GP, Walker EC, Podgor MJ. Is "relative" hypertension a risk factor for vaso-occlusive complications in sickle cell disease? Am J Med Sci. 1993;305:150-156[Medline] [Order article via Infotrieve]. 6. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol. 1988;37:2495-2501[CrossRef][Medline] [Order article via Infotrieve]. 7. Mosseri M, Bartlett-Pandite AN, Wenc K, Isner JM, Weinstein R. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J. 1993;126:338-346[CrossRef][Medline] [Order article via Infotrieve]. 8. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest. 1995;96:1145-1151.
9.
Ibe BO, Morris J, Kurantsin-Mills J, Raj JU.
Sickle erythrocytes induce prostacyclin and thromboxane synthesis by isolated perfused rat lungs.
Am J Physiol.
1997;272:L597-L602
10.
Kaul DK, Liu XD, Fabry ME, Nagel RL.
Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse.
Am J Physiol Heart Circ Physiol.
2000;278:H1799-H1806
11.
French JA 2nd, Kenny D, Scott JP, et al.
Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition.
Blood.
1997;89:4591-4599 12. Vallance P, Collier J, Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res. 1989;23:1053-1057[Medline] [Order article via Infotrieve]. 13. Busse R, Fleming I, Hecker M. Signal transduction in endothelium-dependent vasodilatation. Eur Heart J. 1993;14(suppl I):2-9.
14.
Vanhoutte PM.
Endothelium and control of vascular function: state of the art lecture.
Hypertension.
1989;13:658-667
15.
Dakak N, Husain S, Mulcahy D, et al.
Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction.
Hypertension.
1998;32:9-15
16.
Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A.
Role of NO in flow-induced remodeling of the rabbit common carotid artery.
Arterioscler Thromb Vasc Biol.
1996;16:1256-1262
17.
Langille BL, O'Donnell F.
Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent.
Science.
1986;231:405-407
18.
Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, Talner N.
The heart in sickle cell anemia. The Cooperative Study of Sickle Cell Disease (CSSCD).
Chest.
1995;108:1214-1219 19. Bucherer C, Ladjouzi J, Lacombe C, et al. Effect of deoxygenation on rheological behavior of density separated sickle cell suspension. Clin Hemorheol 1992;12:415-425. 20. Belhassen L, Carville C, Pelle G, et al. Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease. J Cardiovasc Pharmacol. 2000;35:560-563[CrossRef][Medline] [Order article via Infotrieve]. 21. Campillo B, Chabrier PE, Pelle G, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology. 1995;22:1423-1429[CrossRef][Medline] [Order article via Infotrieve]. 22. Carville C, Adnot S, Sediame S, et al. Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure. J Cardiovasc Pharmacol. 1998;32:562-570[CrossRef][Medline] [Order article via Infotrieve]. 23. Lacombe C, Lelièvre JC. Interpretation of rheograms for assessing RBC aggregation and deformability. Clin Hemorheol. 1987;7:47-61. 24. Quemada D. Rheology of concentrated disperse systems, II: a model for non newtonian shear viscosity in steady flows. Rheol Acta. 1978;17:632-642[CrossRef].
25.
Hoeks AP, Samijo SK, Brands PJ, Reneman RS.
Noninvasive determination of shear-rate distribution across the arterial lumen.
Hypertension.
1995;26:26-33 26. Olesen SP, Clapham DE, Davies PF. Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature. 1988;331:168-170[CrossRef][Medline] [Order article via Infotrieve].
27.
Lehoux S, Tedgui A.
Signal transduction of mechanical stresses in the vascular wall.
Hypertension.
1998;32:338-345
28.
Langille BL, Bendeck MP, Keeley FW.
Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow.
Am J Physiol.
1989;256:H931-H939 29. Chien S, Usami S, Delenback J, Bryant CA. Comparative hemorheology-hematological implications of species differences in blood viscosity. Biorheology. 1971;8:35-57[Medline] [Order article via Infotrieve].
30.
Lodato RF.
Decreased O2 consumption and cardiac output during normobaric hyperoxia in conscious dogs.
J Appl Physiol.
1989;67:1551-1559 31. Kaul DK, Fabry ME, Costantini F, Rubin EM, Nagel RL. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest. 1995;96:2845-2853. 32. Bank N, Aynedjian HS, Qiu JH, et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 1996;50:184-189[Medline] [Order article via Infotrieve].
33.
Osei SY, Ahima RS, Fabry ME, Nagel RL, Bank N.
Immunohistochemical localization of hepatic nitric oxide synthase in normal and transgenic sickle cell mice: the effect of hypoxia.
Blood.
1996;88:3583-3588
34.
Uematsu M, Ohara Y, Navas JP, et al.
Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress.
Am J Physiol.
1995;269:C1371-C1378
35.
Topper JN, Cai J, Falb D, Gimbrone MA Jr.
Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress.
Proc Natl Acad Sci U S A.
1996;93:10417-10422
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. A. Pawlak, J. Krejza, W. Rudzinski, J. L. Kwiatkowski, R. Ichord, A. F. Jawad, M. Tomaszewski, and E. R. Melhem Sickle Cell Disease: Ratio of Blood Flow Velocity of Intracranial to Extracranial Cerebral Arteries--Initial Experience Radiology, May 1, 2009; 251(2): 525 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Kaul, X. Zhang, T. Dasgupta, and M. E. Fabry Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H39 - H47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Montalembert, Y. Aggoun, A. Niakate, I. Szezepanski, and D. Bonnet Endothelial-dependent vasodilation is impaired in children with sickle cell disease Haematologica, December 1, 2007; 92(12): 1709 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Guasch, J. Navarrete, K. Nass, and C. F. Zayas Glomerular Involvement in Adults with Sickle Cell Hemoglobinopathies: Prevalence and Clinical Correlates of Progressive Renal Failure J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2228 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kato, V. McGowan, R. F. Machado, J. A. Little, J. Taylor VI, C. R. Morris, J. S. Nichols, X. Wang, M. Poljakovic, S. M. Morris Jr, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease Blood, March 15, 2006; 107(6): 2279 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Pawloski, D. T. Hess, and J. S. Stamler Impaired vasodilation by red blood cells in sickle cell disease PNAS, February 15, 2005; 102(7): 2531 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lemogoum, L. Van Bortel, B. Najem, A. Dzudie, C. Teutcha, E. Madu, M. Leeman, J.-P. Degaute, and P. van de Borne Arterial Stiffness and Wave Reflections in Patients With Sickle Cell Disease Hypertension, December 1, 2004; 44(6): 924 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Belhassen, G. Pelle, J.-L. Dubois-Rande, and S. Adnot Improved endothelial function by the thromboxane a2 receptor antagonist s 18886 in patients with coronary artery disease treated with aspirin J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1198 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Weiner, P. L. Hibberd, P. Betit, A. B. Cooper, C. A. Botelho, and C. Brugnara Preliminary Assessment of Inhaled Nitric Oxide for Acute Vaso-occlusive Crisis in Pediatric Patients With Sickle Cell Disease JAMA, March 5, 2003; 289(9): 1136 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Gladwin, A. N. Schechter, F. P. Ognibene, W. A. Coles, C. D. Reiter, W. H. Schenke, G. Csako, M. A. Waclawiw, J. A. Panza, and R. O. Cannon III Divergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease Circulation, January 21, 2003; 107(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
DB)/DB.
) and control subjects (
). Subjects were asked to breathe
normally for 10 minutes in a facial mask delivering 100% oxygen.
Arterial diameter measurements were performed at baseline and after 5 and 10 minutes of oxygen inhalation. *, P < .01
by ANOVA.
Explorations Fonctionnelles, 51 rue
du Maréchal De Lattre de Tassigny, 94010 CRETEIL, France; e-mail: